Background The effects of omega-3 fatty acids (FAs), such as eicosapentaenoic (EPA) and
docosahexaenoic (DHA) acids, on cardiovascular outcomes are uncertain. We aimed to …

Patients with well-controlled LDL (low-density lipoprotein) levels still have residual
cardiovascular risk associated with elevated triglycerides. Epidemiological studies have …

Aims Despite the effects of statins in reducing cardiovascular events and slowing
progression of coronary atherosclerosis, significant cardiovascular (CV) risk remains …

Abstract Purpose of Review The omega-3 fatty acids (n3-FAs), eicosapentaenoic acid (EPA)
and docosahexaenoic acid (DHA), have recently undergone testing for their ability to reduce …

Interest in the potential cardiovascular (CV) benefits of omega-3 polyunsaturated fatty acids
(Ω-3) began in the 1940s and was amplified by a subsequent landmark trial showing …

Diabetes mellitus is a complex disease. We are increasingly gaining a better understanding
of its mechanisms at the molecular level. From these new insights, better therapeutic …

Background REDUCE-IT was a double-blind trial that randomized 8,179 statin-treated
patients with controlled low-density lipoprotein cholesterol and moderately elevated …

Evidence suggests a close connection between Nonalcoholic Fatty Liver Disease (NAFLD)
and increased cardiovascular (CV) risk. Several cross-sectional studies report that NAFLD is …

Mineral oil is often used as a clinical trial placebo. Pharmaceutical-grade mineral oil consists
of a mixture of saturated hydrocarbons, with a purity and chemical structure that differs …

Twenty percent of deaths in the United States are secondary to cardiovascular diseases
(CVD). In patients with hyperlipidemia and hypertriglyceridemia, studies have shown high …